Mabwell has established an advanced R&D system which covers target discovery, early discovery, druggability, preclinical, clinical research and manufacturing transformation. The International Standard Drug Discovery Platforms and Skillful & Efficient Development Platforms enable us to develop innovative biologics efficiently and submit IND rapidly. We put emphasize on large-scale, fast-growing therapeutic areas including auto-immune diseases, oncology, metabolic disorders, ophthalmologic diseases and infectious diseases, etc. Mabwell has 16 pipeline products. Of these, 1 product has been launched, 2 BLA has been filed, 3 in pivotal trials. We have also undertaken 1 national major scientific and technological special project for "Significant New Drugs Development", 2 projects for National Key R&D Programmes, and several provincial and municipal science and technological innovation projects.
Complied with GMP requirements in China, the US, and Europe.
Adopt both disposable bioreactor and stainless steel bioreactor for the production of drug substance.
Preparation production lines for drug product can complete the dispensation in pre-filled syringes and vials in multiple specifications.
Covers an area of 69.7 thousand square meters.
Capacity of 27,000L/year (Phase I).
Digitalized construction for serving the global market.
EU QP Audit passed.
Antibody production capacity of 4,000L, which can be expanded to 8,000L in a short time. Fusion protein production capacity of 4,000L.
The second phase of industial base, covering an area of 53.4 thousand square meters, focus on the production lines of ADC & recombinant protein.
